<DOC>
	<DOCNO>NCT02895113</DOCNO>
	<brief_summary>The pathophysiology diabetes multifactorial . Beyond genetic susceptibility locus , lot acquire risk factor involve development progression disease . Chronic complication diabetes divide vascular nonvascular . The risk develop complication increase duration hyperglycemia , usually become apparent second decade hyperglycemia . Vascular complication subdivide microvascular ( retinopathy , nephropathy neuropathy ) macrovascular ( coronary artery disease , peripheral arterial disease , cerebrovascular disease ) . It estimate annual decline estimate glomerular filtration rate ( eGFR ) diabetic adult 2.1-2.7 ml/min . While consolidated evidence use aspirin ( ASA ) secondary prevention diabetic patient , consensus use primary prevention ; use ASA patient physician discretion . ASA effective antithrombotic agent inhibits production thromboxane ( Tx ) A2 prostaglandins block cyclooxygenase ( COX ) . In patient treated aspirin , serum TxB₂ level reliable vivo indicator COX-1 inhibition TxA2 , due short half-life artifact associate platelet activation ex vivo . COX present kidney macula densa , medulla interstitium . Experimental animal model demonstrate COX involved regulation renal blood flow . In particular , murine animal model , administration COX inhibitor aspirin celecoxib , observed improvement renal plasma flow eGFR , suggest role Tx progression renal damage However , data relationship aspirin renal function human scarce . In recent work lead large cohort 800 patient non-valvular atrial fibrillation , ASA use associate reduced progression eGFR &lt; 45 ml/min 2 year follow-up . Furthermore , basal level urinary excretion TxB2 , correlate inversely use aspirin decrease eGFR follow-up . The aim study evaluate decline renal function diabetic patient treat low-dose aspirin ( 100 mg/day ) vs. untreated diabetic patient .</brief_summary>
	<brief_title>Aspirin Renal Disease Progression Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Epidemiological data show type 2 diabetes epidemic trend worldwide . The increase food intake , great availability refine grain reduction physical activity , fact , negative effect area . It expect number people suffer diabetes double period 2000-2030.The important increase expect develop country , prevalence obesity rapidly increase . Unlike develop country , Europe US high incidence diabetes primarily relate increased life expectancy general population diabetic people particular , secondary high incidence disease . The Casale Monferrato Study indicate increase 44 % ( 2.6 % vs. 3.8 % ) period 1988-2000 . The prevalence obesity diabetic patient ( Body Mass Index , BMI &gt; 30 kg / m2 ) increase 23 % 34 % . Whereas subject age &lt; 65 year increase prevalence type 2 diabetes non-significant ( 1.1 % vs. 1.7 % ) , age group &gt; 65 year , increase significant ( 6.5 % vs. 9.1 % ) . In particular , double prevalence age ≥80 year record ( 3.5 % vs. 7.2 % ) . The recent data Turin Study show 2003 prevalence overt diabetes 4.9 % 2003 . Thus , double case period 15 year ( 1988-2003 ) ; age group 65-74 year , prevalence rise 13 % age &gt; 74 year 14 % . It also estimate 1.5-2 % population affect misdiagnosed diabetes . The pathophysiology diabetes multifactorial . Beyond genetic susceptibility locus , lot acquire risk factor involve development progression disease . The important Impaired Fasting Glucose ( IFG ) ( odds ratio , OR = 11 ) , Impaired Glucose Tolerance ( IGT ) ( OR = 3.9 ) , weight ( overweight : OR = 3.4 obesity : OR = 9.9 ) , dyslipidemia ( OR = 1.6 ) , hypertension ( OR = 2.3 ) . Chronic complication diabetes divide vascular nonvascular . The risk develop complication increase duration hyperglycemia , usually become apparent second decade hyperglycemia . Vascular complication subdivide microvascular ( retinopathy , nephropathy neuropathy ) macrovascular ( coronary artery disease , peripheral arterial disease , cerebrovascular disease ) . In particular , worsen renal function seem peculiar characteristic patient suffer diabetes . It estimate annual decline estimate glomerular filtration rate ( eGFR ) diabetic adult 2.1-2.7 ml/min . Aspirin Diabetes The efficacy safety acetylsalicylic acid ( aspirin , ASA ) antithrombotic agent assess different subset , apparently healthy people low risk vascular complication ( primary prevention ) , high-risk patient , previous myocardial infarction acute ischemic stroke ( secondary prevention ) . Diabetic patient represent important group treatment ASA carefully consider . The evidence type 2 diabetic patient take glucose-lowering agent similar cardiovascular risk compare non-diabetic previous myocardial infarction , could make reasonable use antiplatelet drug primary prevention strategy cardiovascular disease . However , consolidated evidence use ASA secondary prevention diabetic patient , consensus use primary prevention ; ASA use patient physician discretion . Mechanism action aspirin . Aspirin effective antithrombotic agent inhibits , production thromboxane ( Tx ) A2 prostaglandins block cyclooxygenase ( COX ) enzyme . There describe two isoforms COX , COX-1 , widely express play function gastric cyto-protection , COX-2 express upon external stimulus mainly inflammatory immune cell . Low-dosage ASA inhibit COX-1 , high dosage , ASA inhibit COX-1 COX-2 enzyme . The antiplatelet action ASA via specific inhibition COX platelet , acetylation serine-529 COX-1 . This enzyme possess cyclooxygenase activity [ convert arachidonate prostaglandin G2 ( PGG2 ) ] peroxidase [ convert PGG2 PGH2 , biochemical precursor many prostaglandin Tx ] . In platelet , inhibitory effect result , reduce production prostaglandin TxA2 , strong platelet agonist . This inhibitory effect irreversible TxA2-mediated platelet aggregation restore synthesis new platelet . Thus , ASA administration , platelet aggregation inhibit 7 day . In patient treat low dos aspirin , serum TxB₂ level reliable vivo indicator COX-1 inhibition TxA2 , due short half-life artifact associate platelet activation ex vivo . Both urinary level 11-dehydro-TxB₂ 2.3-dinor-TxB₂ , abundant metabolite TxB₂ , proven platelet activation surrogate . As 11-dehydro-TxB₂ excrete high amount longer half-life , marker choice . Thromboxane bind TP receptor , commonly find platelet , smooth muscle cell , endothelium vessel . They exert vasoconstriction function blood vessel , platelet aggregation induce initial stage coagulation . In particular , Tx entail reduction renal blood flow glomerular filtration rate . Optimal dosage aspirin . Randomized placebo-controlled study show aspirin effective antithrombotic agent dosage range 50 1500 mg/day ; however , long-term clinical efficacy require daily dosage 50 100 mg/day . Patrono et al . assess relationship aspirin dose TxB2 level . This study show single dose 100 mg drug able reduce 98 % concentration serum level Tx first hour . Single dose 100-400 mg able reduce 94-98 % 24 48 hour , inhibition rate 90-92 % 72 hr . Serum Tx decrease normal level period compatible platelet half-life . More 90 % platelet inhibition could maintain one month give 200 mg aspirin every 72 hour . Aspirin , eicosanoids renal function As previously report , ASA able inhibit Tx production inhibit COX ; COX present kidney macula densa , medulla interstitium . In macula densa enzyme seem favour renin production ( eg . salt restriction , use ACE inhibitor , renovascular hypertension ) . Experimental animal model demonstrate COX involved regulation renal blood flow . In particular , murine animal model , administration COX inhibitor aspirin celecoxib , observed improvement renal plasma flow eGFR , suggest role Tx progression renal damage . However , data relationship aspirin renal function human available . In recent work include large cohort 800 patient non-valvular atrial fibrillation , use aspirin associate reduced progression eGFR &lt; 45 ml/min 2 year follow-up . In particular , patient receive aspirin incidence GFR &lt; 45 ml/min 15 % vs. 5 % treat aspirin 100 mg/day . Furthermore , basal level urinary excretion TxB2 , correlate inversely use aspirin decrease eGFR follow-up .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Diagnosis type 2 diabetes : random blood glucose ≥ 200 mg / dl , fast blood glucose ≥ 126 mg/dl , blood glucose 2 hour oral glucose tolerance test ( 75 g ) ≥200 mg/dl , treatment glucoselowering agent . 1 . History cardiovascular cerebrovascular event ; 2 . Presence inadequate glycaemic control ( glycosylated haemoglobin ≥8 % ) ; 3 . Clinical diagnosis type 1 diabetes ( diagnosis diabetes insulin use 35 year age ) ; 4 . Patients renal impairment G4 stage ( eGFR &lt; 30 ml/min ) baseline ; 5 . Chronic active infection evidence malignancy last 5 year ; 6 . Autoimmune systemic disease ; 7 . Cardiac arrhythmia ; 8 . Use nonsteroidal antiinflammatory drug , vitamin supplement , antiplatelet agent previous 30 day ; 9 . Liver Failure ( eg cirrhosis ) ; 10 . Use anticoagulant ; 11 . Life expectancy &lt; 1 year ; 12 . Known allergy aspirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Aspirin</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Renal function</keyword>
	<keyword>Thromboxane</keyword>
</DOC>